Safety and Immunogenicity of MVA-EBO Z and ChAd3-EBO Z in Healthy UK Volunteers

Phase 1 trial of MVA-EBO Z and cAd3-EBOV in Ebola virus disease (EVD) (5 arms), sponsored by University of Oxford. Primary endpoints: Number of participants who experience adverse events following first-in-human administration of MVA-EBO Z alone at 24 weeks, Severity of adverse events following first-in-human administration of MVA-EBO Z alone at 24 weeks and 2 more. Started May 2015; status: terminated.